Amgen Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (135)

View All

Latest Posts

About This Stock More About This Stock
Amgen Pops $2.7 Bln Dose Of Risky Chinese Medicine
Article By: Lipper Alpha Insight
Monday, November 4, 2019 2:11 PM EST
Amgen’s Chinese deal could be good medicine. The pharma giant is paying around $2.7 billion for a 20.5% stake in biotech group BeiGene.
In this article: AMGN Also: CELG, BGNE
Read
Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen
Article By: ChinaBio® Today
Sunday, November 3, 2019 1:34 AM EST
BeiGene, a Beijing cancer biopharma, announced a blockbuster collaboration with Amgen. I-Mab, a Shanghai biopharma, has filed to IPO; Aesthetic Medical International Holdings, a Shenzhen aesthetics company, completed a $30 million IPO on NASDAQ.
In this article: LLY, AMGN, BGNE, AIH, SNCA
Read
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
Article By: Benzinga
Friday, November 1, 2019 7:38 AM EST
Here's a roundup of top developments in the biotech space over the last 24 hours.
In this article: AMGN, BGNE, MNK, PRTK, IDYA, CDNA, BLUE Also: HOTH, AGN, AZN, BMY, GSK, RMD, ACOR, ACRX, ALIM, AMAG, BCRX, CERS, IMGN, NURO, RMTI, CELG, VRTX, ABBV, AGIO, REPH, RETA, PRTO, MGNX, OPGN, MGEN, DOVA, DRNA, DCPH, TRVI, OYST, RAPT, ARDS, MIRM, ITRM, COCP, CYCN, GMAB
Read
Amgen (AMGN) Q3 Earnings And Revenues Top Estimates
Article By: Zacks Investment Research
Tuesday, October 29, 2019 7:50 PM EST
Amgen came out with quarterly earnings of $3.66 per share, beating the Zacks Consensus Estimate of $3.51 per share. This compares to earnings of $3.69 per share a year ago.
In this article: AMGN
Read
3 Big Drug/Biotech Stocks Set To Beat Q3 Earnings Estimates
Article By: Zacks Investment Research
Saturday, October 12, 2019 10:00 AM EST
Overall, relatively newer drugs have been driving the top line of most of the big shots backed by higher demand - a trend we expect to have benefited third-quarter sales.
In this article: LLY, ALXN, AMGN Also: JNJ
Read
All Posts

PARTNER HEADLINES

Latest Tweets for $AMGN

No tweets yet!

$AMGN

Comments Status Updates
July 2017 Stock Considerations
Dick Kaplan • 7/3/2017 3:14:44 AM

I read that #Repatha sales for this quarter are down significantly so be careful with $AMGN.

1 to 1 of 1 comments